MedMira Inc. Stock Soars After HIV Test Approved

Approval of an HIV antibody test by a U.S. agency with a $15-billion budget to fight AIDS internationally has sent MedMira Inc. stock soaring. The Halifax bioscience company saw its stock rise 67 per cent, to $1.27 a share Monday on the TSX Venture Exchange before dropping to $1.20 a share, after it announced last week that its HIV antibody test, Reveal G3, has been approved for purchase by the U.S. Agency for International Development.